Other News

Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

First clinical gene therapy program for PKP2-ACM, a devastating inherited heart disease affecting approximately 50,000 people in the U.S. and EU Robust preclinical proof of concept studies showed RP-A601 decreased arrhythmias and increased survival in the PKP2 knockout mouse model Initiating Phase 1 trial start-up activities and rapidly working towards first […]

Element Science Adds Kathy Jeffery as Chief People Officer

Ms. Jeffery brings over 25 years of best-in-class people leadership for health technology companies on their journey to establish a culture of growth and sustained excellence SAN FRANCISCO–(BUSINESS WIRE)–Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced […]

EDWARDS’ AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA

LOS ANGELES, May 7, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company’s innovative RESILIA tissue. The data, which represent the longest clinical follow-up for Edwards’ bioprosthetic surgical aortic valve with RESILIA […]

Renibus Reports Positive Final Results from Phase 2 Study of RBT-1, a First-in-Class Preconditioning Agent for Patients Undergoing Cardiothoracic Surgery, at the American Association for Thoracic Surgery (AATS) Meeting

RBT-1 achieved the primary biomarker endpoint, as well as several key clinical outcome endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery– RBT-1 as a preconditioning agent has the potential to provide patient benefits in multiple surgical settings where organ injury during surgery increases […]

CardiaCare Names Ken Nelson Chairman of its Board of Directors

Digital health and medtech leader brings 20 years of cardiac innovation and commercialization experience to startup developing AI powered neuromodulation wearable for non-invasive atrial fibrillation treatment REHOVOT, Israel, May 8, 2023 /PRNewswire/ — CardiaCare, a clinical stage digital therapeutic company developing the world’s first non-invasive, neuromodulation wearable for atrial fibrillation treatment, announced today that Ken […]

UCARDIA ANNOUNCES ACQUISITION OF PHAS3; LAUNCHES CARDIOLOGIST PRACTICE REMOTE PATIENT MONITORING OFFERING

AUSTIN, Texas and ST. LOUIS, May 8, 2023 /PRNewswire/ — Ucardia, a cardiac conditioning software developer, announced today that it has reached an agreement to acquire Phas3, a pioneer in home-based cardiac rehab and fellow industry leader. This acquisition will result in a comprehensive, market-leading solution for providers, payers, and consumers, covering all facets […]

Microbot Medical Initiates Preparations for First-In-Human (FIH) Cases in Brazil for the LIBERTY® Robotic System

Distinguished publisher and lecturer, Interventional Radiologist Prof. Francisco Cesar Carnevale Expected to Perform the World’s First Clinical Cases at the Prestigious Institute of Radiology at the University of Sao Paulo Medical School Hospital HINGHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the […]